logo

Epizyme, Inc. (EPZM)



Trade EPZM now with
  Date
  Headline
10/10/2018 11:26:17 AM Epizyme - What's Next?
10/10/2018 6:46:10 AM Epizyme To Present Updated Data On Tazemetostat From Full Phase 2 Study Cohort In Epithelioid Sarcoma At ESMO
10/5/2018 4:06:40 PM Epizyme Closes Public Offering Of 9.58 Mln Shares Of Common Stock At $9/share
10/2/2018 10:28:49 PM Epizyme Prices Public Offering Of 8.33 Mln Shares At $9.00/shr
10/2/2018 4:02:59 PM Epizyme Announces Proposed Public Offering Of Common Stock
9/24/2018 6:34:50 AM Epizyme Says U.S. FDA Lifts Partial Clinical Hold On Tazemetostat Clinical Program
8/2/2018 7:20:17 AM Epizyme Q2 Net Loss $29.1 Mln Or $0.42/Shr Vs Loss $28.0 Mln Or $0.48/Shr Last Year
6/15/2018 5:37:30 AM Epizyme Reports Positive Updated Interim Data From Phase 2 Study Of Tazemetostat
5/18/2018 7:29:18 AM Wedbush Is Cutting Epizyme, Inc. (EPZM) FY19 Estimate To -1.67 From -1.53
5/18/2018 7:28:55 AM Wedbush Is Lowering Epizyme, Inc. (EPZM) Q4 19 Estimate To -0.43 From -0.36
5/18/2018 7:28:11 AM Wedbush Is Lowering Epizyme, Inc. (EPZM) Q3 19 Estimate To -0.42 From -0.39
5/18/2018 7:27:48 AM Wedbush Is Cutting Epizyme, Inc. (EPZM) Q2 19 Estimate To -0.41 From -0.39
5/18/2018 7:27:41 AM Wedbush Is Cutting Epizyme, Inc. (EPZM) Q1 19 Estimate To -0.41 From -0.39
5/18/2018 7:27:26 AM Wedbush Is Cutting Epizyme, Inc. (EPZM) FY18 Estimate To -1.85 From -1.79
5/18/2018 7:27:13 AM Wedbush Is Lowering Epizyme, Inc. (EPZM) Q4 18 Estimate To -0.44 From -0.39